Caribou Biosciences 

$1.6
0
-$0.01-0.62% Thursday 08:25

Statistics

Day High
1.62
Day Low
1.59
52W High
-
52W Low
-
Volume
738
Avg. Volume
-
Mkt Cap
149.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16MarExpected
Q3 2025
Next
-0.35
-0.34
-0.32
-0.3
Expected EPS
-0.310006
Actual EPS
N/A

Financials

-1,491.95%Profit Margin
Unprofitable
2021
2022
2023
2024
19.99MRevenue
-298.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRBU.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the CRISPR gene editing space, directly competing with Caribou Biosciences in developing gene-edited therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a leader in the CRISPR gene editing field, making it a direct competitor to Caribou Biosciences in gene-based medicine.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR gene editing arena, competing with Caribou Biosciences in the development of gene editing therapies.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor to Caribou Biosciences in the precision genetic medicine field.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing with Caribou Biosciences in the development of genomic therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is involved in cell therapy, particularly CAR-T, which competes with Caribou Biosciences' CRISPR-engineered cell therapies.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies, competing with Caribou Biosciences in the cell therapy space.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies works on immune-driven medicine, which overlaps with Caribou Biosciences' work on engineered cell therapies.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences provides sequencing technologies that are crucial for gene editing research, indirectly competing with Caribou Biosciences by enabling gene editing advancements.

About

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Show more...
CEO
Dr. Rachel E. Haurwitz Ph.D.
Employees
147
Country
US
ISIN
US1420381089

Listings

0 Comments

Share your thoughts

FAQ

What is Caribou Biosciences stock price today?
The current price of CRBU.BOATS is $1.6 USD — it has decreased by -0.62% in the past 24 hours. Watch Caribou Biosciences stock price performance more closely on the chart.
What is Caribou Biosciences stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Caribou Biosciences stocks are traded under the ticker CRBU.BOATS.
What is Caribou Biosciences market cap?
Today Caribou Biosciences has the market capitalization of 149.55M
When is the next Caribou Biosciences earnings date?
Caribou Biosciences is going to release the next earnings report on March 16, 2026.
What were Caribou Biosciences earnings last quarter?
CRBU.BOATS earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.35 USD resulting in a +15.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Caribou Biosciences revenue for the last year?
Caribou Biosciences revenue for the last year amounts to 19.99M USD.
What is Caribou Biosciences net income for the last year?
CRBU.BOATS net income for the last year is -298.21M USD.
How many employees does Caribou Biosciences have?
As of February 07, 2026, the company has 147 employees.
In which sector is Caribou Biosciences located?
Caribou Biosciences operates in the Health Care sector.
When did Caribou Biosciences complete a stock split?
Caribou Biosciences has not had any recent stock splits.
Where is Caribou Biosciences headquartered?
Caribou Biosciences is headquartered in Berkeley, US.